CoChat

Sensitivity and specificity of different methods for cystic fibrosis-related diabetes screening: is the oral glucose tolerance test still the standard?

Mainguy, Catherine, Bellon, Gabriel, Delaup, Véronique, Ginoux, Tiphanie, Kassai-Koupai, Behrouz, Mazur, Stéphane, Rabilloud, Muriel, Remontet, Laurent, Reix, Philippe · 2017 · Journal of Pediatric Endocrinology and Metabolism

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Cystic fibrosis-related diabetes (CFRD) is a late cystic fibrosis (CF)-associated comorbidity whose prevalence is increasing sharply lifelong. Guidelines for glucose metabolism (GM) monitoring rely on the oral glucose tolerance test (OGTT). However, this test is neither sensitive nor specific. The aim of this study was to compare sensitivity and specificity of different methods for GM monitoring in children and adolescents with CF. METHODS: Continuous glucose monitoring system (CGMS), used as the reference method, was compared with the OGTT, intravenous glucose tolerance test (IGTT), homeostasis model assessment index of insulin resistance (HOMA-IR), homeostasis model assessment index of β-cell function (HOMA-%B) and glycated haemoglobin A1C. Patients were classified into three groups according to CGMS: normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and diabetes mellitus (DM). RESULTS: Twenty-nine patients (median age: 13.1 years) were recruited. According to CGMS, 11 had DM, 12 IGT and six NGT, whereas OGTT identified three patients with DM and five with IGT. While 13 of 27 had insulin deficiency according to IGTT, there was 19 of 28 according to HOMA-%B. According to HOMA-IR, 12 of 28 had insulin resistance. HOMA-%B was the most sensitive method for CFRD screening [sensitivity 91% (95% CI), specificity 47% (95% CI) and negative predictive value 89% (95% CI)]. CONCLUSIONS: OGTT showed the weak capacity to diagnose DM in CF and should no longer be considered as the reference method for CFRD screening in patients with CF. In our study, HOMA-%B showed promising metrics for CFRD screening. Finally, CGMS revealed that pathological glucose excursions were frequent even early in life.

Overview

Integrity signals

Registry

Crossref · 10.1515/jpem-2016-0184

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 43 references

Research works printed but not linked: 47

  1. 2014, Glucose tolerance in infants and young children with CF, Pediatr Pulmonol, 49, S216
  2. 2004, Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study, Diabetes, 53, 1782, 10.2337/diabetes.53.7.1782 · DOI · Paper page
  3. 2014, International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2014. Management of cystic fibrosis-related diabetes in children and adolescents, Pediatr Diabetes, 15, 65
  4. 2009, Validation of continuous glucose monitoring in children and adolescents with cystic fibrosis: a prospective cohort study, Diabetes Care, 32, 1020, 10.2337/dc08-1925 · DOI · Paper page
  5. 2014, Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test, J Cyst Fibros, 13, 80, 10.1016/j.jcf.2013.06.001 · DOI
  6. 2007, Glucose tolerance, insulin secretion, and insulin sensitivity in children and adolescents with cystic fibrosis and no prior history of diabetes, J Pediatr, 151, 653, 10.1016/j.jpeds.2007.05.012 · DOI
  7. 2013, Exogenous insulin requirements do not differ between youth and adults with cystic fibrosis related diabetes, Pediatr Diabetes, 14, 295, 10.1111/pedi.12014 · DOI · Paper page
  8. 2011, Low-dose insulin therapy in patients with cystic fibrosis and early-stage insulinopenia prevents deterioration of lung function: a 3-year prospective study, J Pediatr Endocrinol Metab, 24, 449
  9. 2013, Homeostasis model assessment of insulin resistance for evaluating insulin sensitivity in patients with type 2 diabetes on insulin therapy, Endocr J, 60, 283, 10.1507/endocrj.ej12-0320 · DOI
  10. 2014, Glucose tolerance in infants and young children with CF, Pediatr Pulmonol, 49, S216
  11. 2013, Registre français de la mucoviscidose– Bilan des données 2013
  12. 2015, Insulin resistance, β-cell dysfunction and differences in curves of plasma glucose and insulin in the intermediate points of the standard glucose tolerance test in adults with cystic fibrosis, Endocrinol Nutr, 62, 91
  13. 2010, Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society, Diabetes Care, 33, 2697, 10.2337/dc10-1768 · DOI · Paper page
  14. 2006, Prevalence and determinants of insulin resistance among U.S. adolescents: a population-based study, Diabetes Care, 29, 2427, 10.2337/dc06-0709 · DOI · Paper page
  15. 2015, Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex, Am J Respir Crit Care Med, 191, 194, 10.1164/rccm.201403-0576oc · DOI · Paper page
  16. 2008, Continuous glucose monitoring in cystic fibrosis patients according to the glucose tolerance, Horm Metab Res, 40, 502, 10.1055/s-2008-1062723 · DOI · Paper page
  17. 2014, Glucose-induced electrical activities and insulin secretion in pancreatic islet β-cells are modulated by CFTR, Nat Commun, 5, 4420, 10.1038/ncomms5420 · DOI · Paper page
  18. 2010, Abnormal glucose tolerance in children with cystic fibrosis: the predictive role of continuous glucose monitoring system, Eur J Endocrinol, 162, 705, 10.1530/eje-09-1020 · DOI · Paper page
  19. 2015, The ΔF508 mutation in the cystic fibrosis transmembrane conductance regulator is associated with progressive insulin resistance and decreased functional beta-cell mass in mice, Diabetes, 64, 4112, 10.2337/db14-0810 · DOI
  20. 2000, Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline, Am J Respir Crit Care Med, 162, 891, 10.1164/ajrccm.162.3.9904075 · DOI · Paper page
  21. 2009, International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes, Diabetes Care, 32, 1327, 10.2337/dc09-9033 · DOI · Paper page
  22. 2015, Elevation of one hour plasma glucose during oral glucose tolerance testing: 1-hour plasma glucose and cystic fibrosis, Pediatr Pulmonol, 50, 963, 10.1002/ppul.23237 · DOI
  23. 2011, Elevation of 1-hour plasma glucose during oral glucose tolerance testing is associated with worse pulmonary function in cystic fibrosis, Diabetes Care, 34, 292, 10.2337/dc10-1604 · DOI · Paper page
  24. 2016, The 1-h oral glucose tolerance test glucose and insulin values are associated with markers of clinical deterioration in cystic fibrosis, Acta Diabetol, 53, 359, 10.1007/s00592-015-0791-3 · DOI
  25. 2010, Oral glucose tolerance testing in children with cystic fibrosis, Pediatr Diabetes, 11, 487, 10.1111/j.1399-5448.2009.00632.x · DOI · Paper page
  26. 2014, Early assessment of glucose abnormalities during continuous glucose monitoring associated with lung function impairment in cystic fibrosis patients, J Cyst Fibros, 13, 478, 10.1016/j.jcf.2013.11.005 · DOI
  27. 2012, Insulin production and resistance in cystic fibrosis: effect of age, disease activity, and genotype, J Endocrinol Invest, 35, 246
  28. 2015, Age- and sex-dependent distribution of OGTT-related variables in a population of cystic fibrosis patients, J Clin Endocrinol Metab, 100, 2963, 10.1210/jc.2015-1512 · DOI
  29. 2005, Use of waist circumference to predict insulin resistance: retrospective study, Br Med J, 330, 1363, 10.1136/bmj.38429.473310.ae · DOI · Paper page
  30. 2015, 178 Glucose tolerance in cystic fibrosis patients over a 3-year period (DIAMUCO study), J Cyst Fibros, 14, S103, 10.1016/s1569-1993(15)30355-6 · DOI
  31. 1998, Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation, Diabet Med, 15, 539, 10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s · doi:10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s
  32. 2008, Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis, J Pediatr, 152, 540, 10.1016/j.jpeds.2007.09.025 · DOI
  33. 2005, Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents, Pediatrics, 115, e500, 10.1542/peds.2004-1921 · DOI · Paper page
  34. 2003, Validation of interstitial fluid continuous glucose monitoring in cystic fibrosis, Diabetes Care, 26, 1940, 10.2337/diacare.26.6.1940-a · DOI
  35. 2011, Kinetics of insulin secretion and glucose intolerance in adult patients with cystic fibrosis, Horm Metab Res, 43, 355, 10.1055/s-0031-1275270 · DOI
  36. 2009, Mechanisms of glucose intolerance in cystic fibrosis, Diabet Med, 26, 582, 10.1111/j.1464-5491.2009.02738.x · DOI
  37. 1995, Glucose tolerance in patients with cystic fibrosis: five year prospective study, Br Med J, 311, 655, 10.1136/bmj.311.7006.655 · DOI · Paper page
  38. 2005, Can waist circumference identify children with the metabolic syndrome?, Arch Pediatr Adolesc Med, 159, 740, 10.1001/archpedi.159.8.740 · DOI · Paper page
  39. 1985, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man, Diabetologia, 28, 412, 10.1007/bf00280883 · DOI · Paper page
  40. 2016, Glycated hemoglobin cannot yet be proposed as a screening tool for cystic fibrosis related diabetes, J Cyst Fibros, 15, 258, 10.1016/j.jcf.2016.02.005 · DOI
  41. 2015, Screening of glucose metabolism derangements in pediatric cystic fibrosis patients: how, when, why, Acta Diabetol, 52, 633, 10.1007/s00592-015-0743-y · DOI
  42. 2008, No relationship between mean plasma glucose and glycated haemoglobin in patients with cystic fibrosis-related diabetes, Diabetes Metab, 34, 568, 10.1016/j.diabet.2008.05.010 · DOI
  43. 2009, Validation of insulin secretion indices in cystic fibrosis patients, J Cyst Fibros, 8, 378, 10.1016/j.jcf.2009.08.007 · DOI
  44. 2013, Registre français de la mucoviscidose– Bilan des données 2013
  45. 2012, Abnormal endocrine pancreas function at birth in cystic fibrosis ferrets, J Clin Invest, 122, 3755, 10.1172/jci60610 · DOI · Paper page
  46. 2013, Update on cystic fibrosis-related diabetes, J Cyst Fibros, 12, 318, 10.1016/j.jcf.2013.02.008 · DOI · Paper page
  47. 2004, Conventional measures underestimate glycaemia in cystic fibrosis patients, Diabet Med, 21, 691, 10.1111/j.1464-5491.2004.01219.x · DOI · Paper page

Cited by

Metadata

Authors
Mainguy, C., Bellon, G., Delaup, V., Ginoux, T., Kassai-Koupai, B., Mazur, S., Rabilloud, M., Remontet, L., & Reix, P.
Affiliations
  • Hôpital Femme Mère Enfant (FR)
  • Lyon 1 Université (FR)
  • Centre National de la Recherche Scientifique (FR)
Corresponding author
Mainguy, Catherine
Venue
Journal of Pediatric Endocrinology and Metabolism
Published
2017-01-01
Volume
30
Issue
1
Pages
27-35
ISSN
  • 0334-018X (ISSN-L)
  • 2191-0251
OpenAlex
W2565462754
Cited by
37
References
43
Citations by year
2026: 2 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 7 · 2021: 6 · 2020: 3 · 2019: 2 · 2018: 4 · 2017: 3
FWCI
2.69
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Pediatric Endocrinology and Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
cystic fibrosis-related diabetes, diabetes screening, oral glucose tolerance test, continuous glucose monitoring, HOMA-β, HOMA-IR, intravenous glucose tolerance test, glycated haemoglobin A1c, impaired glucose tolerance, insulin resistance, beta-cell function, children and adolescents, sensitivity and specificity
MeSH terms
Adolescent, Blood Glucose, Child, Cystic Fibrosis, Diabetes Mellitus, Female, Follow-Up Studies, France, Glucose Tolerance Test, Glycated Hemoglobin, Humans, Insulin Resistance, Male, Mass Screening, Prognosis, Prospective Studies, Sensitivity and Specificity, Biomarkers, Comorbidity, Prevalence, Glucose Intolerance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.